Chinese veterinary medicine and vaccine companies could increasingly look at buying established Latin American animal health businesses rather than spending years building operations from the ground up, according to a recent industry analysis published on LinkedIn by animal health consultant Bernardo Otero.
Otero, founder of Nexus Animal Health, specifically names Chinese manufacturers Lunan, CAHIC and Ringpu among companies he says are evaluating Latin American entry.
His central argument is important: the question may no longer be whether Chinese animal health companies enter Latin America, but how and how soon they enter.
Disclaimer
However, an important distinction is needed. Publicly available evidence reviewed for this report does not confirm that these three companies have announced any acquisitions of Latin American animal health companies. Otero’s article is an industry forecast, not a confirmed deal announcement.
Why Latin America is becoming difficult for Chinese animal health companies to ignore
The numbers explain much of the interest. One recent market estimate valued the Latin American animal health market at $7.2 billion in 2025 and projects it could reach $16.2 billion by 2033, representing annual growth of 10.8% between 2026 and 2033.
Brazil alone offers a powerful example. Official data from Brazil’s animal health industry association Sindan show that the country’s animal health market reached R$12.8 billion in sales in 2025, up 7.9% from 2024.
Cattle products accounted for 47% of industry sales. Poultry was another strong area, while vaccines and parasite-control products remained among the industry’s largest product groups. A year earlier, Brazil’s animal health market had grown 10.1% to R$11.9 billion. Pet animal products represented 27% of industry sales in 2024, compared with only 15% in 2014.
For Chinese veterinary companies searching for growth outside their domestic market, these are difficult numbers to overlook.
China-Latin America trade has already crossed $500 billion
The animal health discussion is also part of a much larger economic change. Trade between China and Latin America and the Caribbean reached approximately $515 billion in 2024, compared with just $12 billion at the beginning of the century.
In 2025, China announced about $10 billion in new credit lines for Latin America and the Caribbean. Brazil also attracted billions of dollars in announced Chinese investment commitments.
The relationship continued to deepen into 2026. Inter-American Development Bank data reported in June showed that Latin American exports to China increased 25% in the first quarter of 2026 compared with a year earlier. Imports from China increased 29%.
Until now, much Chinese investment in Latin America has focused on energy, mining, infrastructure, electric vehicles and technology. Otero’s analysis raises a new question: could animal health become part of the next investment wave?
Why buying a local animal health company may be faster than starting from zero
Animal health is different from many consumer industries. A foreign company cannot simply ship veterinary medicines into a country and begin selling them.
Products need local registration. Companies need distributors. Veterinarians and farmers need to trust the brand. Sales teams need knowledge of local livestock production and disease problems.
Otero estimates that registering veterinary medicines or vaccines in major Latin American markets can take 18 to 48 months, depending on the country, product and quality of the registration file. Distribution can be an even bigger problem.
Many established Latin American animal health companies have spent decades building relationships with veterinary clinics, livestock farms, poultry companies and regional distributors.
Buying such a company can provide an international investor with registered products, a local workforce, manufacturing knowledge and an existing sales network.
Previous acquisitions show why the strategy can work
Latin America’s animal health industry has already seen major international companies use acquisitions to build their regional businesses. One of the best-known examples was Merck Animal Health and its acquisition of a controlling interest in Brazilian veterinary company Vallée.
Expert analysis values the 2017 transaction at about $400 million for a 93% interest. Vallée brought more than 100 animal health products and operations or market presence across several Latin American countries.
The lesson is simple. A foreign company buying a strong regional business is not only buying products. It may also be buying years of registrations, customer relationships, manufacturing experience and local knowledge. For a Chinese animal health company, this could be particularly valuable.
CAHIC already sells veterinary products in nearly 60 countries and regions One company specifically highlighted is China Animal Husbandry Industry Co., Ltd. (CAHIC).
CAHIC is a Shanghai-listed animal health and nutrition company and is part of a Chinese state-owned agricultural group. According to CAHIC’s own company information, its veterinary vaccines and medicines are used in nearly 60 countries and regions.
The company operates across four major areas: animal vaccines, veterinary medicines, animal feed and additives, and raw material trading. It also supplies vaccines for major animal diseases, including avian influenza and foot-and-mouth disease. This is significant for Latin America.
The region has major cattle, poultry and pig industries. Disease prevention, vaccines and farm productivity are large commercial markets.
CAHIC therefore has products that broadly fit important Latin American livestock needs. What is not yet publicly confirmed is an announced CAHIC acquisition target in Latin America.
Ringpu has more than 500 animal health products
Another major Chinese Animal Health company is Ringpu Biology as a company to watch out for.
Founded in 1998, Ringpu is listed in China and describes itself as one of the country’s leading animal health companies. Company information shows more than 2,700 employees, 20 group companies, 11 veterinary medicine manufacturing sites and over 500 animal health products.
Its products cover poultry, livestock, ruminants and pets. Ringpu also operates in vaccines, veterinary medicines, feed additives and raw materials.
Ringpu reported RMB168 million in research spending in 2022, equal to 8.08% of revenue, according to company information. It also lists more than 400 research and engineering staff.
A company of this scale has the manufacturing and product base to expand internationally. The difficult part is building local access. That is exactly where buying an established Latin American company could make strategic sense.
Again, there is currently a gap between strategic logic and confirmed transaction. No specific Ringpu acquisition in Latin America was publicly confirmed in the sources reviewed for this article.
Brazil may be the first LA market everyone watches
Brazil is the obvious centre of any discussion about Chinese animal health investment in Latin America. The country has one of the world’s largest cattle industries and is a major producer and exporter of beef and poultry.
Its animal health market reached R$12.8 billion in 2025. Cattle alone generated nearly half of sector sales. Brazil also has established domestic animal health companies, veterinary manufacturing plants and experienced technical teams.
From an investor’s perspective, this creates a rare combination: a large local market and companies with products that may also be sold in other Latin American countries. The strongest targets may therefore not necessarily be the largest companies.
Mid-sized businesses with registered veterinary products, modern manufacturing plants and strong regional distribution could be particularly attractive.
Pet health could become the next acquisition battleground
The Chinese opportunity is not limited to cattle and poultry. Brazilian industry data show how quickly the pet health market has developed. Pet products increased from 15% of Brazilian animal health sales in 2014 to 27% in 2024.
Next Latin American acquisition wave could increasingly target pet supplements, specialist pet health products, skin treatments and veterinary diagnostics.
This would represent a change from earlier deals, which often focused heavily on livestock vaccines and veterinary medicines. Pet owners are spending more on long-term disease care, testing and preventive health.
That creates opportunities for companies with specialist products rather than only large, traditional veterinary medicine portfolios.
Latin American animal health companies may also start buying
There is another side to the story. Latin American companies including Biogénesis Bagó, Ourofino Saúde Animal, Vencofarma and Tecnovax could themselves lead further regional consolidation.
This creates an interesting possibility. Chinese companies may not be the only buyers looking for attractive Latin American animal health businesses.
They could find themselves competing with European, US and Latin American companies for the same assets. That competition could increase the value of businesses with strong product registrations, good manufacturing standards and established sales networks.
Is a Chinese acquisition wave already happening?
Not yet—not based on publicly confirmed animal health transactions reviewed for this report.
This is the most important fact-checking point and while the wider economic data clearly support growing China-Latin America trade and investment, no acquisition is imminent, maybe in works but no annoucements just as yet.
CAHIC’s own records confirm that it already sells veterinary products in nearly 60 countries and regions. Ringpu has the product range, manufacturing network and research base of a large animal health company.
The business conditions for Chinese animal health investment in Latin America are becoming stronger, and industry analysts now see acquisitions as a likely route into the market.
